Dear Daja ,

In the current issue of the OncoWuXi Newsletter, we share updates on our services and newly established capabilities.
 
The OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of WuXi Biology, our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases. We are your ideal partner for enabling technological breakthroughs and accelerating cancer drug discovery.

Immunology

Ovalbumin (OVA)-induced Rheumatoid Arthritis in Rabbits


(1)   Establishment and evaluation of OVA-induced rheumatoid arthritis in rabbits



(2)   Summary list of animal models for inflammation and auto-immune diseases


Read More

Targeted Oncology

BCR-ABL Related Cell lines and In Vivo Models


(1)   Human leukemia cell lines carrying BCR-ABL fusion gene, tested with Imatinib, Ponatinib, Olverembatinib and Dasatinib in vitro and in vivo


(2)   Genetically engineered Ba/F3 cell line carrying BCR-ABL fusion gene, tested with Imatinib, Ponatinib and Olverembatinib in vitro and in vivo


(3)   Genetically engineered Ba/F3 cell line carrying BCR-ABL-T315I mutation, tested with Imatinib, Ponatinib and Olverembatinib in vitro and in vivo


Read More


CD79B-targeted ADC Related Models


(1)   12 human lymphoma CDX models expressing CD79B


(2)   Lymphoma PDX models expressing CD79B



(3)   Case studies: anti-tumor efficacy evaluation of R-CHOP combination chemotherapy and CD79B ADC in CD79B positive lymphoma PDX models


Read More


Genetically Engineered ERα Mutant MCF-7 Human Breast Cancer Models


(1)   Genetically engineered ERα Y537S and ERα D538G mutant MCF-7 cell lines


(2)   Anti-tumor efficacy evaluation in ERα D538G mutant MCF-7 xenograft model


Read More

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
 
Best regards,
WuXi AppTec OncoWuXi Team